The Europe Microbiome Diagnostics Market would witness market growth of 17.0% CAGR during the forecast period (2023-2030).
The Germany market dominated the Europe Microbiome Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $24,425.8 Thousands by 2030. The UK market is showcasing a CAGR of 16% during (2023 - 2030). Additionally, The France market would register a CAGR of 17.9% during (2023 - 2030).
It is crucial in understanding the link between the gut microbiome and metabolic disorders such as obesity, type 2 diabetes, and metabolic syndrome. Research has shown that gut microbiota composition and function alterations can influence host metabolism, energy balance, and insulin sensitivity. It can identify microbial biomarkers associated with metabolic dysfunction, providing insights into disease mechanisms and potential therapeutic targets.
Likewise, the microbiome plays a central role in modulating immune function and responses. It studies how the gut microbiome interacts with the immune system and influences immune-mediated diseases such as allergies, autoimmune disorders, and inflammatory conditions. By profiling the microbiome-immune axis, it can identify microbial signatures associated with immune dysregulation and inflammatory diseases, informing therapeutic interventions and immune-modulating strategies. Also, the skin microbiome has emerged as a key player in maintaining skin health and integrity. It is utilized to study the composition and diversity of microbial communities on the skin and their role in dermatological conditions such as acne, eczema, psoriasis, and wound healing. Understanding the skin microbiome’s dynamics and its interaction with the host can inform personalized skincare interventions and therapeutic approaches for various dermatological ailments.
In addition, the high prevalence of respiratory diseases in Europe drives demand for microbiome diagnostics in research and clinical settings. According to Eurostat, respiratory illnesses accounted for 347 867 deaths in the EU in 2020 or 6.7% of all fatalities among citizens. In 2020, the proportion of deaths from respiratory diseases in Malta, Denmark, and Ireland was considerably higher than the EU average, at 10.5 %, 10.4 %, and 10.0 %, respectively. As research continues to unravel the complex interplay between the respiratory microbiome and respiratory health, it will play an increasingly critical role in shaping the future of respiratory medicine in Europe and beyond. Thus, the high prevalence of respiratory diseases and the expansion of the pharmaceutical industry in the region is propelling the market’s growth.
Based on Application, the market is segmented into Disease Diagnostics (Gastrointestinal Disorders, Metabolic Diseases and Others) and Research Application. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Sample, the market is segmented into Fecal, Saliva, Skin, and Others. Based on Technology, the market is segmented into 16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics and Others. Based on End User, the market is segmented into Hospitals, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Microbiome Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $24,425.8 Thousands by 2030. The UK market is showcasing a CAGR of 16% during (2023 - 2030). Additionally, The France market would register a CAGR of 17.9% during (2023 - 2030).
It is crucial in understanding the link between the gut microbiome and metabolic disorders such as obesity, type 2 diabetes, and metabolic syndrome. Research has shown that gut microbiota composition and function alterations can influence host metabolism, energy balance, and insulin sensitivity. It can identify microbial biomarkers associated with metabolic dysfunction, providing insights into disease mechanisms and potential therapeutic targets.
Likewise, the microbiome plays a central role in modulating immune function and responses. It studies how the gut microbiome interacts with the immune system and influences immune-mediated diseases such as allergies, autoimmune disorders, and inflammatory conditions. By profiling the microbiome-immune axis, it can identify microbial signatures associated with immune dysregulation and inflammatory diseases, informing therapeutic interventions and immune-modulating strategies. Also, the skin microbiome has emerged as a key player in maintaining skin health and integrity. It is utilized to study the composition and diversity of microbial communities on the skin and their role in dermatological conditions such as acne, eczema, psoriasis, and wound healing. Understanding the skin microbiome’s dynamics and its interaction with the host can inform personalized skincare interventions and therapeutic approaches for various dermatological ailments.
In addition, the high prevalence of respiratory diseases in Europe drives demand for microbiome diagnostics in research and clinical settings. According to Eurostat, respiratory illnesses accounted for 347 867 deaths in the EU in 2020 or 6.7% of all fatalities among citizens. In 2020, the proportion of deaths from respiratory diseases in Malta, Denmark, and Ireland was considerably higher than the EU average, at 10.5 %, 10.4 %, and 10.0 %, respectively. As research continues to unravel the complex interplay between the respiratory microbiome and respiratory health, it will play an increasingly critical role in shaping the future of respiratory medicine in Europe and beyond. Thus, the high prevalence of respiratory diseases and the expansion of the pharmaceutical industry in the region is propelling the market’s growth.
Based on Application, the market is segmented into Disease Diagnostics (Gastrointestinal Disorders, Metabolic Diseases and Others) and Research Application. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Sample, the market is segmented into Fecal, Saliva, Skin, and Others. Based on Technology, the market is segmented into 16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics and Others. Based on End User, the market is segmented into Hospitals, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Illumina, Inc.
- Becton, Dickinson and Company
- Genetic Analysis AS
- Microba Life Sciences Limited
- BioMe Oxford Ltd
- Viome Life Sciences, Inc.
- GoodGut S.L.U. (HIPRA, S.A.)
- Sun Genomics
- Origin Sciences Limited
- Decode Age
Market Report Segmentation
By Application- Disease Diagnostics
- Gastrointestinal Disorders
- Metabolic Diseases
- Others
- Research Application
- Reagents & Kits
- Instruments
- Fecal
- Saliva
- Skin
- Others
- 16S rRNA Sequencing
- Shot Gun Metagenomics
- Metatranscriptomics
- Others
- Hospitals
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Europe Microbiome Diagnostics Market by Application
Chapter 6. Europe Microbiome Diagnostics Market by Product
Chapter 7. Europe Microbiome Diagnostics Market by Sample
Chapter 8. Europe Microbiome Diagnostics Market by Technology
Chapter 9. Europe Microbiome Diagnostics Market by End User
Chapter 10. Europe Microbiome Diagnostics Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- Illumina, Inc.
- Becton, Dickinson and Company
- Genetic Analysis AS
- Microba Life Sciences Limited
- BioMe Oxford Ltd
- Viome Life Sciences, Inc.
- GoodGut S.L.U. (HIPRA, S.A.)
- Sun Genomics
- Origin Sciences Limited
- Decode Age
Methodology
LOADING...
